Study on Prevention of Preeclampsia using Calcium Supplements in Early Pregnancy
Authors/Creators
- 1. Department of Obstetrics and Gynaecology, NSCB Medical College Jabalpur, Madhya Pradesh India
Description
Introduction: As recommended by WHO, regular calcium supplementation reduces the risk of preeclampsia. Limited food intake communities at high risk of preeclampsia also benefit from calcium supplementation. Preeclampsia and hypertension diseases are a leading cause of maternal mortality. Calcium supplementation is a low-risk, affordable measure to improve maternal and newborn health. Preeclampsia has complex causes and can only be treated by delivering the placenta. Calcium supplementation prevents nearly 50% of preeclampsia cases. Preeclampsia affects 2% of pregnancies and contributes to perinatal and maternal fatalities, mostly in low- and middle-income nations. Aims and Objective: To analyze the efficiency of calcium supplements in early pregnancy in preventing preeclampsia. Method: This study involved 90 participants in a randomized, double-blind, placebo-controlled design to evaluate a new obstetric care intervention’s efficacy and safety. Participants were assigned to either the Calcium group, receiving 1.5 g of Calcium daily after 20 weeks’ gestation, or the Placebo group. Primary and secondary outcomes were assessed after a 12-week period, and compliance was measured through surveys and follow-up. Inclusion criteria included women with a history of preeclampsia or eclampsia and an interest in future pregnancies. Exclusion criteria encompassed factors such as age, existing pregnancy, use of calcium supplements, certain medical conditions, and personal choices regarding contraception and consent. Results: The study found that the Placebo group had a higher rate of complications before allocation. Compliance rates were similar between the groups, indicating comparable adherence to the intervention. Pregnancy outcomes, including pregnancy loss rates and the frequencies of live births and pregnancies progressing to 20 weeks of gestation, did not significantly differ between the Calcium and Placebo groups. Preeclampsia occurrence showed no statistically significant difference between the groups. Other outcomes did not show significant changes, including gestational blood pressure, proteinuria, pregnancy loss, preeclampsia severity, preeclampsia onset, and maternal problems. However, more individuals in the Calcium group required postpartum hospitalization of 7 days or longer compared to the Placebo group. The study found no statistically significant differences between the two groups in most outcomes assessed. Conclusion: The study has concluded that Calcium can significantly prevent preeclampsia in early pregnancy.
Abstract (English)
Introduction: As recommended by WHO, regular calcium supplementation reduces the risk of preeclampsia. Limited food intake communities at high risk of preeclampsia also benefit from calcium supplementation. Preeclampsia and hypertension diseases are a leading cause of maternal mortality. Calcium supplementation is a low-risk, affordable measure to improve maternal and newborn health. Preeclampsia has complex causes and can only be treated by delivering the placenta. Calcium supplementation prevents nearly 50% of preeclampsia cases. Preeclampsia affects 2% of pregnancies and contributes to perinatal and maternal fatalities, mostly in low- and middle-income nations. Aims and Objective: To analyze the efficiency of calcium supplements in early pregnancy in preventing preeclampsia. Method: This study involved 90 participants in a randomized, double-blind, placebo-controlled design to evaluate a new obstetric care intervention’s efficacy and safety. Participants were assigned to either the Calcium group, receiving 1.5 g of Calcium daily after 20 weeks’ gestation, or the Placebo group. Primary and secondary outcomes were assessed after a 12-week period, and compliance was measured through surveys and follow-up. Inclusion criteria included women with a history of preeclampsia or eclampsia and an interest in future pregnancies. Exclusion criteria encompassed factors such as age, existing pregnancy, use of calcium supplements, certain medical conditions, and personal choices regarding contraception and consent. Results: The study found that the Placebo group had a higher rate of complications before allocation. Compliance rates were similar between the groups, indicating comparable adherence to the intervention. Pregnancy outcomes, including pregnancy loss rates and the frequencies of live births and pregnancies progressing to 20 weeks of gestation, did not significantly differ between the Calcium and Placebo groups. Preeclampsia occurrence showed no statistically significant difference between the groups. Other outcomes did not show significant changes, including gestational blood pressure, proteinuria, pregnancy loss, preeclampsia severity, preeclampsia onset, and maternal problems. However, more individuals in the Calcium group required postpartum hospitalization of 7 days or longer compared to the Placebo group. The study found no statistically significant differences between the two groups in most outcomes assessed. Conclusion: The study has concluded that Calcium can significantly prevent preeclampsia in early pregnancy.
Files
IJPCR,Vol15,Issue6,Article130.pdf
Files
(370.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:9c7633bf1d9671910ca95e6dd601542c
|
370.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-03
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue6,Article130.pdf
- Development Status
- Active
References
- 1. World Health Organization. Guideline: Calcium supplementation in pregnant women. 2013, World Health Organization: Geneva, Switzerland 2. Hypertension in Pregnancy: Report of the ACOG Task Force on Hypertension in Pregnancy. 2013, American Congress of Obstetricians and Gynecologists. 3. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4:97–104. 4. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. J Obstet Gynaecol Can 2014; 36:416–41. 5. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, Paech MJ, Said JM. The SOMANZ guideline for the management of hypertensive disorders of pregnancy. 2014, Society of Obstetric Medicine of Australia and New Zealand. 6. Magee LA, Brown MA, Hall DDR, Gupte S, Hennessy A, Ananth Karumanchi S, et al. The hypertensive disorders of pregnancy: the 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis and management recommendations for international practice. Pregnancy Hypertens. 2021; 27: 148– 69. 7. Wang H, Bhutta ZA, Coates MM, Coggeshall M, Dandona L, Diallo K, et al. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053): 1725– 74. 8. Kassebaum NJ, Barber RM, Dandona L, Hay SI, Larson HJ, Lim SS, et al. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053): 1775– 812 9. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Preeclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014; 121: 14– 24. 10. Duley L: The global impact of preeclampsia and eclampsia. Semin Perinatol. 2009; 33 (3): 130-137. 11. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. Lancet. 2006, 367 (9516): 1066-1074. 12. Villar J, Say L, Shennan A, Lindheimer M, Duley L, CondeAgudelo A: Methodological and technical issues related to the diagnosis, screening, prevention andtreatment of preeclampsia and eclampsia. International Journal of Gynecology & Obstetrics. 2004, 85 (Suppl 1): S28-S41. 13. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018 Oct 1;10(10):CD001059. 14. Kumar A, Devi SG, Batra S, Singh C, Shukla DK. Calcium supplementation for the prevention of preeclampsia. Int J Gynaecol Obstet. 2009 Jan; 104(1): 32-6. 15. Bucher HC, Guyatt GH, Cook RJ, Hatala R, Cook DJ, Lang JD, Hunt D. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA. 1996 Apr 10;275(14):1113-7. 16. Repke JT, Villar J. Pregnancy-induced hypertension and low birth weight: the role of calcium. Am J Clin Nutr. 1991 Jul;54(1 Suppl):237S-241S. 17. Cifkova R. Why is the treatment of hypertension in pregnancy still so difficult? Expert Rev Cardiovasc Ther. 2011; 9:647–9. 18. Meher S, Duley L. Interventions for treating preeclampsia and its consequences: generic protocol. Cochr Database Systemat Rev. 2009; 2:253– 61. 19. Camargo EB, Moraes LF, Souza CM, Akutsu R, Barreto JM, da Silva EM, et al. Survey of calcium supplementation to prevent preeclampsia: the gap between evidence and practice in Brazil. BMC Pregn Childb. 2013; 13: 206. 20. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstetr Gynecol. 2019; 133:1. 21. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, BlomströmLundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39:3165–241. 22. Hofmeyr GJ, Lawrie TA, Atallah NÁ, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochr Database Systemat Rev. 2018; 10: Cd001059. 23. Young T. Cochrane column: dietary calcium supplementation and preeclampsia. Int J Epidemiol. 2007; 36:290–1. 24. Belizán JM, Villar J, Repke J. The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. Am J Obstet Gynecol. 1988; 158:898–902. 25. Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of preeclampsia and related podocyte injury. Kidney Int. (2014) 86:275–85. 26. Aghamohammadi A, Zafari M. Calcium supplementation in pregnancy and prevention of hypertensive disorders in elderly women. Sci Asia. 2015; 41:259–62.